Table 1.
Clinical and sociodemographic characteristics of EPHIC participants experiencing virologic failure of first-line cART (N = 94).
| Variable | Summary Statistic | N | |||
|---|---|---|---|---|---|
| Age at baseline, years, Median (IQR) | 12 (9–14) | 94 | |||
| Gender, % male | 60% | 94 | |||
| pVL at baseline, log10 copies/mL, Median (IQR) | 3.9 (3.6–4.6) | 94 | |||
| pVL at failure, log10 copies/mL, Median (IQR) | 4.2 (3.8–4.7) | 94 | |||
| CD4+ T-cell count at baseline, cells/mm3, Median (IQR) | 500 (247–781) | 92 | |||
| CD4+ T-cell count at ART initiation, cells/mm3, Median (IQR) | 276 (163–613) | 89 | |||
| ART duration at baseline, months, Median (IQR) | 35 (18–70.5) | 89 | |||
| Weight for age at baseline, Z-score *, Median (IQR) | −1.5 (−2.1–(−0.6)) | 89 | |||
| Height for age at baseline, Z-score *, Median (IQR) | −1.3 (2.1–(−0.4)) | 89 | |||
| combination Antiretrovial T regimen at baseline, % patients | |||||
| NRTI | 93 | ||||
| 3TC+ | AZT | 66% | |||
| d4T | 29% | ||||
| TDF | 3% | ||||
| ABC | 2% | ||||
| NNRTI | 93 | ||||
| EFV | 22% | ||||
| NVP | 77% | ||||
| WHO Clinical Stage at baseline, % patients Stage 1 | 85% | 94 | |||
* Height- and Weight-for-age Z score was measured using WHO Anthropomorphic Software [61], where a Z-score of <−2 is indicative of malnutrition.